{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:45:32Z","timestamp":1769827532657,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T00:00:00Z","timestamp":1471219200000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>The findings of the Women's Health Initiative study in 2002 marginalized the use of hormone replacement therapy and established bisphosphonates as the first line of treatment for osteoporosis.\u00a0 Denosumab could be used in selected patients. Although bisphosphonates only maintain the structure of bone complete with any accumulated structural or material faults, their bone selectivity and effectiveness in reducing the risk of fractures, together with their low cost, have left little room for improvement for new antiresorptives. The osteoanabolic teriparatide increases new bone formation, but it is administered for up to 2 years only and the cost remains a consideration. Similar restrictions are expected to apply to an anti\u2010sclerostin antibody, which could be evaluated by the U.S. Food and Drug Administration in the near future. Cathepsin K\u2013inhibiting antibody could be an alternative if approved; although an antiresorptive, it maintains bone formation, in contrast with bisphosphonates, and can be probably used for long\u2010term treatment.\u00a0 Rare adverse effects of bisphosphonates, namely osteonecrosis of the jaws and atypical femoral fractures, have been disproportionally emphasized relative to their benefits\/harm ratio. Treatment of osteoporosis is a long process, and many patients will require treatment with more than one type of drug over their lifetime.<\/jats:p>","DOI":"10.1111\/nyas.13166","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T19:56:47Z","timestamp":1471291007000},"page":"5-13","source":"Crossref","is-referenced-by-count":25,"title":["Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least?"],"prefix":"10.1111","volume":"1376","author":[{"given":"Michael","family":"Pazianas","sequence":"first","affiliation":[{"name":"Oxford University Institute of Musculoskeletal Sciences  Oxford United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"Odense Patient Data Explorative Network University of Southern Denmark and Odense University Hospital  Odense Denmark"},{"name":"Department of Medicine Holb\u00e6k Hospital  Holb\u00e6k Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.040117"},{"key":"e_1_2_9_4_1","unstructured":"Tsai J.et\u00a0al.2015. Effect of denosumab (DMAB) and teriparatide (TPTD) transitions on peripheral bone mineral density (BMD) and microarchitecture: the DATA\u2010switch HR\u2010pQCT study. [abstract #1055]. S18. Washington DC: ASBMR."},{"key":"e_1_2_9_5_1","first-page":"325","article-title":"Long\u2010term treatment with bisphosphonates and their safety in postmenopausal osteoporosis","volume":"6","author":"Pazianas M.","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809493"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1513724"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.273.5279.1236"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.8.1444"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-014-2944-6"},{"key":"e_1_2_9_11_1","unstructured":"MERCK.http:\/\/www.mercknewsroom.com\/news-release\/research-and-development-news\/merck-announces-data-pivotal-phase-3-fracture-outcomes-st. Accessed June 18 2016."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2015.30.4.429"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.212"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-016-3503-0"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2972"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808692"},{"key":"e_1_2_9_18_1","unstructured":"Goldstein R.S. D.Portman&J.Symons.2015. Endometrial effects of lasofoxifene: results from two phase 3 osteoporosis prevention trials [abstract].Menopause22: 1372(#1989362)."},{"key":"e_1_2_9_19_1","unstructured":"European Medicines Agency. Marketing authorisation for Fablyn.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000977\/human_med_000783.jsp&mid=WC0b01ac058001d124. Accessed June 18 2016."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S52291"},{"key":"e_1_2_9_21_1","unstructured":"EMC. Binosto 70 mg effervescent tablets.https:\/\/www.medicines.org.uk\/emc\/medicine\/30896. Accessed June 18 2016."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket236"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070413"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3718"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2013.02.008"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080216"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305224"},{"key":"e_1_2_9_29_1","unstructured":"Amgen Press Release. Accessed February 21 2016.https:\/\/www.amgen.com\/media\/news-releases\/2016\/02\/amgen-and-ucb-announce-positive-top-line-results-from-the-phase-3-study-of-romosozumab-in-postmenopausal-women-with-osteoporosis\/. Accessed June 18 2016."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.5.537"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4351"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1521"},{"key":"e_1_2_9_33_1","unstructured":"European Medicines Agency. European Medicines Agency recommends that Protelos\/Osseor remain available but with further restrictions. Accessed June 18 2016.http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/02\/news_detail_002031.jsp&mid=WC0b01ac058004d5c1."},{"key":"e_1_2_9_34_1","unstructured":"Direct Healthcare Professional Communication. New restricted indication and monitoring recommendations for the use of Protelos (strontium ranelate). Accessed June 18 2016.http:\/\/www.servier.com\/sites\/default\/files\/DHPC_Protelos\/Strontium%20ranelate%20-%20DHPC%20-%20UK.pdf."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2708"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-23639-1_2"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4181"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000380960"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2565"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-014-0237-9"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2489"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.091201"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnyas.13166","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nyas.13166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T03:26:30Z","timestamp":1694489190000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/nyas.13166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/nyas.13166"],"URL":"https:\/\/doi.org\/10.1111\/nyas.13166","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}